Time the pharma industry popped the quality pill
The cost of bad quality can have a devastating impact on a company, beyond financial liability. In the context of medicines that impact is on patients. Though this may seem like an obvious observation, it formed the central theme of a recent pharma industry conclave, reiterating the need for a quality-oriented culture in drug companies. With representation of drug regulators from India, the US, the UK and France, the conclave came at a time when some of the industry's top drugmakers are facing regulatory action in foreign markets or are in the process of remediation efforts. Naturally, the message going out from the conclave was unambiguous. There is no place for short-cuts. Companies need to get their operations right the first time, have early-warning systems to pick up quality or data transgressions, and they need to identify the root cause and take remedial actions to fix the problem. After all, those who fail to learn from history are doomed to repeat it, sai...